Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

157.54 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
A 5-Stock Portfolio With A "Healthy" Yield
Healthcare stocks provides portfolio stability. Plus, they usually pay dividends and healthcare is a steady growth market. Better still, healthcare is responsible for some of the most reliable... 
Via Talk Markets
AbbVie: High Yield At A Low P/E
Over the first half of this year, pharmaceutical giant AbbVie has traded in a narrow range while meme stocks, cryptocurrencies, and other get-rich-quick schemes have diverted investor attention away... 
Via Talk Markets
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.... 
Via Benzinga
46 Firms Going Ex-Dividend, Including Oracle, Accenture And PNC Financial
There are several well-known large-cap stocks going ex-dividend this week 
Via Talk Markets
3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season
The big drug companies are set for the second-quarter earnings season, which begins later this month. 
Via Talk Markets
The Dividend Aristocrats
Let's take a look at some of the Dividend Aristocrats, as well as their size and longevity. 
Via Talk Markets
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Jim Lebenthal Likes AbbVie Stock At Its Current Price
It's a great time to invest in pharmaceutical companies such as AbbVie Inc (NYSE: 
Via Benzinga
Got $5,000? Buy and Hold These 3 Value Stocks for Years
Looking to buy and forget a stock? Look no further. 
Via The Motley Fool
Topics Economy
Exposures Economy
3 Dividend Stocks That Are Dirt Cheap Right Now
Most stocks are priced at a premium. But these are bargains that also offer solid dividends. 
Via The Motley Fool
3 Warren Buffett Stocks to Buy in July
You might call these the legendary investor's "A-list." 
Via The Motley Fool
Can Evolus Disrupt the Botox Market?
This small-cap stock is going after a billion-dollar market. 
Via The Motley Fool
These 25 Stocks Are the Worst to Own in July
The major benchmarks are celebrating a winning first half of 2021. However, despite all the optimism, it is always a good idea to keep an eye on stocks that have a tendency to underperform at this... 
Via Talk Markets
AbbVie: Is the Price Right for Long-Term Investment?
The pharma giant's stock is up 18% in the past year. Have investors missed the boat or is the stock still a buy? 
Via The Motley Fool
New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly... 
Via Benzinga
Who Are The Dividend Aristocrats In 2021?
Legendary investor George Soros once said, “Good investing should be boring”. But an increase in volatile themes today suggests this maxim has gone ignored by at least some market participants. 
Via Talk Markets
These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval
Some might be surprised to see income-paying stocks among the ARK Invest founder's high-growth picks. 
Via The Motley Fool
Johnson & Johnson Reaches $230M Settlement With New York To End Sale Of Opioids Nationwide
The company has said that it has not marketed opioids in the U.S. since 2015 and discontinued the business in 2020. JNJ did not admit liability in settling with New York State, Nassau, and Suffolk... 
Via Talk Markets
Johnson & Johnson Reaches $230M Settlement With New York State To End Sale Of Opioids Nationwide
On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state,... 
Via Benzinga
Nike And Wells Fargo Lead The SPY Higher Friday
U.S. indices continued higher Friday after President Joe Biden declared that the White House had struck an infrastructure deal with a bipartisan gr... 
Via Benzinga
FDA To Miss Action Dates For AbbVie's Upadacitinib Application For Psoriatic Arthritis, Ankylosing Spondylitis
The 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
2 Dividend Stocks That Could Be Paying You 10% Within 5 Years
They already provide investors with above-average payouts today. 
Via The Motley Fool
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
This Is Warren Buffett's Best Dividend Stock by Far
There's a lot to like with this Buffett stock. 
Via The Motley Fool
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong... 
Via Talk Markets
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.